International Collaborative Ovarian Neoplasm studies (3): a trial of paclitaxel with carboplatin in the first-line treatment of ovarian cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN57157825

Enrollment

2000

Registered

2001-02-28

Start date

1995-03-27

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer Cancer Ovarian cancer

Interventions

1. One group receives paclitaxel in combination with carboplatin 2. The other group receives a control treatment of either single-agent carboplatin or CAP (cyclophosphamide, doxorubicin and cisplatin)

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1. Chemotherapy indicated 2. No previous chemotherapy or radiotherapy 3. No contraindication to chemotherapy

Exclusion criteria

Exclusion criteria: Does not meet inclusion criteria

Design outcomes

Primary

Measure	Time frame
Survival time - time to progression, quality of life, health economics	—

Secondary

Measure	Time frame
Not provided at time of registration	—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Mar 21, 2026